Famciclovir
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Recurrent Herpes Labialis
Conditions
Recurrent Herpes Labialis
Trial Timeline
Oct 1, 2003 → Jul 1, 2007
NCT ID
NCT00248144About Famciclovir
Famciclovir is a approved stage product being developed by Novartis for Recurrent Herpes Labialis. The current trial status is completed. This product is registered under clinical trial identifier NCT00248144. Target conditions include Recurrent Herpes Labialis.
What happened to similar drugs?
3 of 20 similar drugs in Recurrent Herpes Labialis were approved
Approved (3) Terminated (0) Active (17)
🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00878072 | Phase 2/3 | Completed |
| NCT00448227 | Phase 2 | Completed |
| NCT00098046 | Phase 3 | Completed |
| NCT00098059 | Phase 3 | Completed |
| NCT00129818 | Approved | Completed |
| NCT00248144 | Approved | Completed |
| NCT00219310 | Approved | Completed |
| NCT00171990 | Phase 3 | Completed |
Competing Products
20 competing products in Recurrent Herpes Labialis